Novartis AG Sponsored ADR (NVS)
Novartis says rare muscle disease drug shows promise in early trial
Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.
Novartis Reports Positive Data for Neuromuscular Disorder Drug
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
Implied Volatility Surging for Novartis Stock Options
Investors need to pay close attention to NVS stock based on the movements in the options market lately.
Novartis: Revenue Lags In Q1, Outlook Unchanged
Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year guidance was reaffirmed. Entresto U.S. sales eroded faster than I expected, but easier Y/Y comps and robust pipeline support a return to growth. NVS's key products Kisqali, Kesimpta, Leqvio, and Pluvicto continue to outperform, and Rhapsido is off to a strong start in the CSU market with additional clinical trial readouts on the way.
Novartis shares fall after weak Q1 hit by Entresto competition
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugmaker declined about 3% in premarket trading on Tuesday following the earnings release.
Novartis CEO: We knew these first two quarters would be bumpy
Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
Novartis receives European Commission approval for Rhapsido skin disease drug
Novartis has received European Commission approval for its drug Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU), the Swiss drugmaker said on Monday.
Unveiling Novartis (NVS) Q1 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Evergreen Capital Management LLC Has $6.51 Million Stock Position in Novartis AG $NVS
Evergreen Capital Management LLC boosted its stake in Novartis AG (NYSE: NVS) by 68.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,245 shares of the company's stock after acquiring an additional 19,155 shares during the period. Evergreen Capital
Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)
Novartis AG ended 2025 on a high note. On February 27, NVS stock reached a 52-week high of $170.46. However, a correction began after that, in my view, partly due to a 33.2% quarter-over-quarter decline in sales of heart failure drug Entresto to $1.25 billion in Q4.
Novartis Bolsters Immunology Pipeline With Excellergy Deal
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
